Page 54 - Bioterrorism

53

• Pregnant or breastfeeding or females of childbearing potential who refuse to use an
acceptable method of birth control
• Surgery planned during the study period
• Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,
neomycin or polymyxin or any other component of the study vaccine
• Receipt of another vaccine within 3 weeks prior to Visit 1 or planned vaccination within 3
weeks following the last study vaccination
• History of (or current) drug or alcohol abuse
• Any condition, which, in the opinion of the Investigator, might interfere with the
evaluation of the study objectives.

Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00434733

Locations

Poland
Centrum Badań Farmakologii Klinicznej monipol
Kraków, Poland, 30-969
Sponsors and Collaborators
Novartis
Novartis Vaccines
Investigators

Study Chair: Novartis Vaccines and Diagnostics GmbH & Co KG Novartis Novartis Vaccines and Diagnostics GmbH & Co KG., Germany
More Information

No publications provided

Study ID Numbers: V87P4, 2006-005428-18
Study First Received: February 12, 2007

Last Updated: April 23, 2008
ClinicalTrials.gov Identifier: NCT00434733 History of Changes

Health Authority: Poland: Central Register of Clinical Trials (CEBK)

Keywords provided by Novartis:
Influenza H5N1, pandemic

Study placed in the following topic categories:
Virus Diseases Influenza, Human
Respiratory Tract Diseases Influenza in Birds
Respiratory Tract Infections Orthomyxoviridae Infections

Additional relevant Mesh terms:
Virus Diseases Respiratory Tract Infections
RNA Virus Infections Influenza, Human
Respiratory Tract Diseases Orthomyxoviridae Infections

ClinicalTrials.gov processed this record on May 17, 2009